Literature DB >> 2906114

Macrophage precursors as natural killer cells against tumor cells and microorganisms.

M Baccarini1, L Hao, T Decker, M L Lohmann-Matthes.   

Abstract

Macrophage precursors cells have been isolated from spleen and liver of mice and have characterized using F4/80 antibody, their proliferative response to CSF-1 and their maturation to macrophages. These nonadherent and nonphagocytic cells exert strong killing of Yac-1 tumor cells and of various microorganisms. Transplantation of these macrophage precursors into lethally irradiated allogenic hosts restores natural killer (NK) activity within 14 days. Macrophage precursors show enhanced NK activity when activated with interleukin 2. FACS analysis of F 4/80 presorted macrophage precursors reveals about 30% of the cells coexpressing NK 1.1. and F 4/80. These data support the assumption that at least a part of the NK cell compartment is derived from the myeloid lineage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906114

Source DB:  PubMed          Journal:  Nat Immun Cell Growth Regul        ISSN: 0254-7600


  4 in total

1.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

2.  Natural killer cells mediate protection induced by a Salmonella aroA mutant.

Authors:  R Schafer; T K Eisenstein
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

3.  Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection.

Authors:  G Karupiah; R V Blanden; I A Ramshaw
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

4.  Cooperative effects of colony-stimulating factor 1 and recombinant interleukin 2 on proliferation and induction of cytotoxicity of macrophage precursors generated from mouse bone marrow cell cultures.

Authors:  H Li; R Schwinzer; M Baccarini; M L Lohmann-Matthes
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.